|
Common name |
B-hSIGLEC15 MC38 | Catalog number | 311049 |
| Aliases | CD33L3, HsT1361, SIGLEC-15 | Disease | Colon carcinoma |
|
Organism |
Mouse |
Strain | C57BL/6 |
| Tissue types | Colon | Tissue | Colon |
Description
Subcutaneous homograft tumor growth of B-hSIGLEC15 MC38 cells. B-hSIGLEC15 MC38 cells (5x105) and wild-type MC38 cells (1x106 ) were subcutaneously implanted into the B-hSIGLEC15 mice (female, 6-8 week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hSIGLEC15 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
B-hSIGLEC15 MC38 tumor cells growth of individual mouse. B-hSIGLEC15 MC38 cells (5x105) and wild-type MC38 cells (1x106) were subcutaneously implanted into B-hSIGLEC15 mice (female, 6-8 week-old, n=6). As shown in panel, B-hSIGLEC15 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
B-hSIGLEC15 MC38 cells were subcutaneously transplanted into B-hSIGLEC15 mice (n=6). At the end of the experiment, tumor cells were harvested and assessed for human SIGLEC15 expression by flow cytometry. As shown, human SIGLEC15 was highly expressed on the surface of tumor cells. Therefore, B-hSIGLEC15 MC38 cells can be used for in vivo efficacy studies of novel SIGLEC15 therapeutics.
